Not really Orabanda. The active ingredient in artimist is one of the drugs that is becoming resistant.
"Disease experts recommend that artemisinin combination therapies (ACT) are best. These combine the artemisinin derivative with another class of drug usually in a tablet form."
"Companion drugs include lumefantrine, mefloquine, amodiaquine, sulfadoxine/pyrimethamine, piperaquine and chlorproguanil/dapsone. Artemisinin derivatives include dihydroartemisinin, artesunate and artemether."
"The benefits of ACTs are their high efficacy, fast action and the reduced likelihood of resistance developing. In order to make best use of them, it is critical to address issues of delivery, access and cost."
If EMS could develop a sublingual spray that combined the both drugs then that would be a very very big deal. Maybe that's what their plans are for SUDA (pure speculation on my part)
bluebush
EMS Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
